HomeAbout Karis Bio

UNMET NEEDSVascular Disease: Needs of Cell Therapy

There is no clinical therapy to effectively treat severe PAD except reducing symptoms and preventing further progression of the disease through lifestyle changes, such as quitting smoking, and exercise. More serious symptoms of PAD may require angioplasty or vascular surgery.

Progressive PAD is initially characterized by intermittent claudication and results in chronic pain and ulceration called CLI. CLI patients are at very high risk of amputation and poor physical function, leading to severe morbidity and mortality and should therefore be treated aggressively. The treatment of CLI has evolved over the past few decades to include broad approaches in medical, interventional, and surgical therapy; still, the major amputation rate is 35% to 50% at 1 year.

MISSIONInnovative Cell Therapy for Cardiovascular Disease: Need New Blood Vessels

Almost all clinical trials with adult stem or progenitor cells showed no or modest effects. There are no clinical trials with hiPSC-EC. Our product will be first-in-class cell therapy product.

The goal of our company is a therapy using hiPSC-ECs for treating critical limb ischemia (CLI). CLI is a serious public health issue for which no adequate treatment is available. Given the prevalence and seriousness of CLI, developing a new therapy for this disease is highly significant. This development will explore both autologous and allogeneic approaches. The initial goal is to develop autologous cell therapy. By avoiding immunological reactions, this would be an ideal approach for patients if successful. The product is a platform that can be used for many other diseases requiring a vascular supply for tissue or organ regeneration. The other disease indications include ischemic heart disease, wound healing, cerebrovascular disease, bone disease, and diabetic complications.

LEADERSHIPFor a Better World with a Great Scientific Innovation

Young-sup Yoon, MD, PhD
First research for developing hiPSC-ECs as a clinical therapeutic agent for cardiovascular diseases

Dr. Young-sup Yoon

CHIEF EXECUTIVE OFFICER

TEAMOne Goal. One Passion. Great Team.

Shin-Jeong Lee, PhD
CHIEF TECNOLOGY OFFICERShin-Jeong Lee, PhD
Song Kim, MD
HEAD OF CLINICAL DEVELOPMENTSong Kim, MD
Sangsung Kim, MS
R&D DIRECTORSangsung Kim, MS
Jay Han, PhD
CHIEF OPERATING OFFICERJay Han, PhD
Karis Bio USA
Seongho Bae, PhD
R&D DIRECTORSeongho Bae, PhD
Karis Bio USA

INVESTORS

https://i0.wp.com/karisbio.com/wp-content/uploads/2021/05/KDB-2.png?fit=225%2C85&ssl=1
https://i1.wp.com/karisbio.com/wp-content/uploads/2021/05/Premier-1.png?fit=225%2C83&ssl=1
https://i0.wp.com/karisbio.com/wp-content/uploads/2021/05/IB-4.png?fit=225%2C85&ssl=1
https://i2.wp.com/karisbio.com/wp-content/uploads/2021/05/seoul-1.png?fit=225%2C85&ssl=1
https://i1.wp.com/karisbio.com/wp-content/uploads/2021/07/Dinv-2.png?fit=225%2C85&ssl=1

PARTNERS

https://i2.wp.com/karisbio.com/wp-content/uploads/2021/05/sevrance-6.png?fit=300%2C113&ssl=1
https://i2.wp.com/karisbio.com/wp-content/uploads/2021/05/Yongin-3.png?fit=300%2C113&ssl=1
https://i1.wp.com/karisbio.com/wp-content/uploads/2021/05/Emory-1.png?fit=300%2C113&ssl=1